Media stories about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2953552966307 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at $7.10 on Friday. Corbus Pharmaceuticals Holdings has a one year low of $5.30 and a one year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. research analysts forecast that Corbus Pharmaceuticals Holdings will post -0.61 earnings per share for the current year.

Several analysts have recently commented on the stock. Noble Financial reiterated a “buy” rating and issued a $16.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, September 29th. Cantor Fitzgerald reiterated a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, September 20th. ValuEngine lowered shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $20.75.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Corbus Pharmaceuticals Holdings (CRBP) Stock Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/24/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-corbus-pharmaceuticals-holdings-crbp-stock-price.html.

In other news, Director David P. Hochman acquired 10,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $7.08 per share, with a total value of $70,800.00. Following the completion of the purchase, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David P. Hochman acquired 5,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average cost of $6.90 per share, for a total transaction of $34,500.00. The disclosure for this purchase can be found here. Insiders have purchased 25,336 shares of company stock worth $175,632 in the last three months. Insiders own 11.90% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.